Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.

Breast cancer (Tokyo, Japan) - 1 Mar 2026

Park Min-Seung, Youn Youngjin, Kim Jee Ah, Cho Eun Hye, Do In-Gu, Woo Hee-Yeon, Park Hyosoon, Kim Eun Young, Kwon Min-Jung

Abstract excerpt

BACKGROUND: Circulating tumor DNA (ctDNA) has emerged as a prognostic biomarker for breast cancer, potentially offering a more comprehensive representation of tumor genetic heterogeneity. In this study, we assessed the prognostic and monitoring values of ctDNA at multiple clinical time points during diagnosis and therapy. METHODS: A total of 119 patients with breast cancer underwent ctDNA analysis using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Class I Phosphatidylinositol 3-Kinases

Share to Disease-Free Survival

Share to Follow-Up Studies

Share to High-Throughput Nucleotide Sequencing

Share to Neoadjuvant Therapy

Source

Identifiers

PMID: 41619106
DOI: 10.1007/s12282-025-01818-z

Genes

PIK3CA
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.PMID 41619106Read ↗

Serial Circulating Tumor DNA Identification Associated with the Efficacy and Prognosis of Neoadjuvant Chemotherapy in Breast CancerSemantic proximity Read ↗

Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.Semantic proximity Read ↗

Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapySemantic proximity Read ↗

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.Semantic proximity Read ↗

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA.Semantic proximity Read ↗

Dynamic ctDNA tracking stratifies individual relapse risk for early triple negative breast cancer patients receiving neoadjuvant chemotherapySemantic proximity Read ↗

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survivalSemantic proximity Read ↗

Clinical application of circulating tumor DNA in breast cancer.Semantic proximity Read ↗

Clinical applications of circulating tumor DNA in monitoring breast cancer drug resistance.Semantic proximity Read ↗

Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study.Semantic proximity Read ↗

Dynamic Analysis of Circulating Tumor DNA to Predict the Prognosis and Monitor the Treatment Response of Patients with Metastatic Triple-negative Breast Cancer: a prospective studySemantic proximity Read ↗

Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.